Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Trends Cancer. 2018 Feb;4(2):119–137. doi: 10.1016/j.trecan.2017.12.007

Table2.

Sipuleucel-T combination therapies in clinical trials for Prostrate Cancer

Study
Start		 Brief Title Condition NCT Identifier Intervention Phase Status as of
December 2017
2012 Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer Metastatic Prostrate Cancer NCT01560923 Sipuleucel-T + Indoximod (IDO pathway inhibitor) 2 Active, not recruiting
2013 A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer Metastatic Prostrate Cancer NCT01981122 Sipuleucel-T + Enzalutamide (Synthetic non-steroidal antiandrogen) 2 Active, not recruiting
2013 Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer Adenocarcinoma of the Prostate; Bone Metastases; Hormoneresistant Prostate Cancer; Recurrent Prostate Cancer; Soft Tissue Metastases Stage IV Prostate Cancer NCT01807065 Sipuleucel-T + External beam radiation therapy 2 Active, not recruiting
2013 Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC) Metastatic castrationresistant Prostate Cancer NCT01818986 Sipuleucel-T + Stereotactic Ablative Body Radiation 2 Recruiting
2013 Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer Prostrate Cancer NCT01706458 Sipuleucel-T + DNA Vaccine (Plasmid DNA encoding human prostatic acid phosphatase) 2 Active, not recruiting
2013 Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T Hormone-Resistant Prostate Cancer; Metastatic Malignant Neoplasm in the Bone; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer NCT01833208 Sipuleucel-T + Radiation Therapy Recruiting
2014 A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer Prostrate Cancer NCT01804465 SipT Treatment + Ipilimumab (Anti-CTLA-4 antibody) 2 Recruiting
2015 Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC Prostrate Cancer NCT02463799 Sipuleucel-T + Radium-223 2 Recruiting
2015 Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing Prostrate Cancer NCT02353715 Sipuleucel-T + Enzalutamide (Synthetic non-steroidal antiandrogen) or Abiraterone acet ate (Androgen synthesis inhibitor) 1 Recruiting
2017 Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer Metastatic Prostrate Cancer NCT03024216 Sipuleucel-T + Atezolizumab (Anti-PDL-1 antibody) 1 Recruiting